Literature DB >> 27935602

Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review.

N Brito-García1, T Del Pino-Sedeño2,3, M M Trujillo-Martín1,3,4, R M Coco5,6, E Rodríguez de la Rúa6,7, I Del Cura-González4,8, P Serrano-Aguilar3,4,9.   

Abstract

The hereditary retinal dystrophies (HRDs) are a group of genetically determined disorders that result in loss of the visual function. There is a lack of standard pharmacological treatments or widely accepted nutritional recommendations. The objective of this review is to summarise the scientific evidence on the effectiveness and safety of nutritional supplements for the treatment of HRDs. We conducted a scientific literature search on Medline and PreMedline, EMBASE, SCI-EXPANDED, SSCI, and The Cochrane Library up to August 2014. Experimental, quasi-experimental and controlled observational studies were selected. Eight studies were ultimately included, seven on retinitis pigmentosa (RP) and one on Best disease. Vitamin A, vitamin E, docosahexaenoic acid (DHA), lutein and β-carotene were assessed. A 15 000 IU daily dose of vitamin A was reported to have shown a small protective effect on the progression of RP, as was the use of the carotenoids lutein and β-carotene. Different DHA doses has no effect on RP or Best disease. No supplement showed severe adverse effects in the selected studies although strong evidence of toxicity exists for high doses of vitamin A and β-carotene in certain populations. The selected studies concluded that there may be a small beneficial effect of vitamin A, lutein and β-carotene on the progression of RP. The limited evidence available indicates some well-designed additional studies on combined supplements strategies may achieve more robust conclusions. Moreover, the scarcity of evidence available on the treatment of HRD other than RP with nutritional supplements supports the need for further research efforts.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27935602      PMCID: PMC5306468          DOI: 10.1038/eye.2016.286

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  33 in total

1.  Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A.

Authors:  Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Robert J Brockhurst; K C Hayes; Elizabeth J Johnson; Ellen J Anderson; Chris A Johnson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer
Journal:  Arch Ophthalmol       Date:  2010-04

Review 2.  Mechanisms of action of docosahexaenoic acid in the nervous system.

Authors:  N Salem; B Litman; H Y Kim; K Gawrisch
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

3.  Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial.

Authors:  Thomas K M Lee; M Thomas Clandinin; Marc Hébert; Ian M MacDonald
Journal:  Can J Ophthalmol       Date:  2010-10       Impact factor: 1.882

4.  Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations.

Authors:  Tomas S Aleman; Artur V Cideciyan; Elizabeth A M Windsor; Sharon B Schwartz; Malgorzata Swider; John D Chico; Alexander Sumaroka; Alexander Y Pantelyat; Keith G Duncan; Leigh M Gardner; Jessica M Emmons; Janet D Steinberg; Edwin M Stone; Samuel G Jacobson
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

5.  Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients.

Authors:  I Chowers; E Banin; S Merin; M Cooper; E Granot
Journal:  Eye (Lond)       Date:  2001-08       Impact factor: 3.775

6.  Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis-{beta}-carotene.

Authors:  Ygal Rotenstreich; Dror Harats; Aviv Shaish; Eran Pras; Michael Belkin
Journal:  Br J Ophthalmol       Date:  2009-12-02       Impact factor: 4.638

7.  A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa.

Authors:  Dennis R Hoffman; Kirsten G Locke; Dianna H Wheaton; Gary E Fish; Rand Spencer; David G Birch
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

Review 8.  Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials.

Authors:  Nathalie Druesne-Pecollo; Paule Latino-Martel; Teresa Norat; Emilie Barrandon; Sandrine Bertrais; Pilar Galan; Serge Hercberg
Journal:  Int J Cancer       Date:  2010-07-01       Impact factor: 7.396

Review 9.  Carotenoids in the retina--a review of their possible role in preventing or limiting damage caused by light and oxygen.

Authors:  W Schalch
Journal:  EXS       Date:  1992

Review 10.  Systematic Review of Randomized Clinical Trials on Safety and Efficacy of Pharmacological and Nonpharmacological Treatments for Retinitis Pigmentosa.

Authors:  Marta Sacchetti; Flavio Mantelli; Daniela Merlo; Alessandro Lambiase
Journal:  J Ophthalmol       Date:  2015-08-03       Impact factor: 1.909

View more
  4 in total

Review 1.  The Role of Vitamin A in Retinal Diseases.

Authors:  Jana Sajovic; Andrej Meglič; Damjan Glavač; Špela Markelj; Marko Hawlina; Ana Fakin
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

2.  NUTRARET: Effect of 2-Year Nutraceutical Supplementation on Redox Status and Visual Function of Patients With Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Lorena Olivares-González; David Salom; Emilio González-García; David Hervás; Natalia Mejía-Chiqui; Mar Melero; Sheyla Velasco; Bianca Tabita Muresan; Isabel Campillo; Nieves Vila-Clérigues; Eduardo López-Briz; Juan Francisco Merino-Torres; José María Millán; José Miguel Soriano Del Castillo; Regina Rodrigo
Journal:  Front Nutr       Date:  2022-03-21

3.  A novel small molecule chaperone of rod opsin and its potential therapy for retinal degeneration.

Authors:  Yuanyuan Chen; Yu Chen; Beata Jastrzebska; Marcin Golczak; Sahil Gulati; Hong Tang; William Seibel; Xiaoyu Li; Hui Jin; Yong Han; Songqi Gao; Jianye Zhang; Xujie Liu; Hossein Heidari-Torkabadi; Phoebe L Stewart; William E Harte; Gregory P Tochtrop; Krzysztof Palczewski
Journal:  Nat Commun       Date:  2018-05-17       Impact factor: 14.919

4.  Establishment of a Rapid Lesion-Controllable Retinal Degeneration Monkey Model for Preclinical Stem Cell Therapy.

Authors:  Guanjie Gao; Liwen He; Shengxu Liu; Dandan Zheng; Xiaojing Song; Wenxin Zhang; Minzhong Yu; Guangwei Luo; Xiufeng Zhong
Journal:  Cells       Date:  2020-11-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.